These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 25424122

  • 1. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K.
    BMC Neurol; 2014 Nov 26; 14():220. PubMed ID: 25424122
    [Abstract] [Full Text] [Related]

  • 2. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
    Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E.
    J Neurol Sci; 2016 Jun 15; 365():190-8. PubMed ID: 27206905
    [Abstract] [Full Text] [Related]

  • 3. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
    Cascione M, Tenenbaum N, Wendt J, Meng X, Schofield L, Cree BAC, PREFERMS investigators.
    Mult Scler Relat Disord; 2018 Oct 15; 25():50-56. PubMed ID: 30036854
    [Abstract] [Full Text] [Related]

  • 4. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M, Italian iMed-Web database.
    Brain; 2015 Nov 15; 138(Pt 11):3275-86. PubMed ID: 26362907
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Fox E, Edwards K, Burch G, Wynn DR, LaGanke C, Crayton H, Hunter SF, Huffman C, Kim E, Pestreich L, McCague K, Barbato L, EPOC study investigators.
    Mult Scler Relat Disord; 2014 Sep 15; 3(5):607-19. PubMed ID: 26265273
    [Abstract] [Full Text] [Related]

  • 6. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G.
    Contemp Clin Trials; 2015 Mar 15; 41():69-74. PubMed ID: 25545026
    [Abstract] [Full Text] [Related]

  • 7. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰.
    Hunter SF, Thomas FP, Cascione M, Williams IM, Meng X, Schofield L, Weiss JL, Tenenbaum N, Cree BAC, PREFERMS investigators.
    Mult Scler Relat Disord; 2020 Oct 15; 45():102346. PubMed ID: 32717684
    [Abstract] [Full Text] [Related]

  • 8. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 15; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 9. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA, Kamal KM, Pawar G.
    J Manag Care Spec Pharm; 2017 Jun 15; 23(6):666-676. PubMed ID: 28530523
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    Braune S, Lang M, Bergmann A, NeuroTransData Study Group.
    J Neurol; 2016 Feb 15; 263(2):327-333. PubMed ID: 26645389
    [Abstract] [Full Text] [Related]

  • 11. Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
    Tuncer MA, Kürtüncü M, Terzi M, Uygunoğlu U, Göncüoğlu C, Yüceyar AN, Ekmekçi Ö, Türkoğlu R, Soysal A, Köseoğlu M, Boz C, Beckmann Y, Turan ÖF, Demirkıran DM, Akman FG, Altunrende B, Cantürk İA, Birday E, Özcan A, Kamişli Ö, Özen NPA, Çelik RGG, Balcı FB, Efendi H, Sarıkaya C, Akçalı A, Toprak MK, Kabay SC, Kızılay F, Sevim MS, Gazaloğlu GB, Demir CF, Balgetir F, Kıylıoğlu N, Sarıahmetoğlu H, Ölmez Ç, Mavi K, Yüksel S, Işık N, Saip S, Karabudak R, Siva A, Eraksoy M.
    Turk J Med Sci; 2023 Feb 15; 53(1):323-332. PubMed ID: 36945929
    [Abstract] [Full Text] [Related]

  • 12. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 13. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA.
    Curr Med Res Opin; 2012 May 24; 28(5):767-80. PubMed ID: 22462530
    [Abstract] [Full Text] [Related]

  • 14. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
    Cascione M, Wynn D, Barbato LM, Pestreich L, Schofield L, McCague K.
    J Med Econ; 2013 Jul 24; 16(7):859-65. PubMed ID: 23647445
    [Abstract] [Full Text] [Related]

  • 15. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, Varga S, Herrera V, Ko JJ.
    J Manag Care Spec Pharm; 2019 Apr 24; 25(4):490-498. PubMed ID: 30917079
    [Abstract] [Full Text] [Related]

  • 16. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA, Trenova A, Llaneza MA, Fischer J, Lus G, von Bredow D, Lara N, Lam E, Van Hoef M, Bakshi R.
    BMC Neurol; 2017 Aug 09; 17(1):156. PubMed ID: 28793876
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L, Guo S, Kinter E, Fay M.
    J Med Econ; 2016 Jul 09; 19(7):684-95. PubMed ID: 26947984
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H, Hu F, Zhang Y, Li K.
    J Neurol; 2020 Dec 09; 267(12):3489-3498. PubMed ID: 31129710
    [Abstract] [Full Text] [Related]

  • 19. Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    Abdel-Dayem MA, Shaker ME, Gameil NM.
    J Neuroimmunol; 2019 Dec 15; 337():577062. PubMed ID: 31521828
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T.
    J Med Econ; 2016 Dec 15; 19(4):432-42. PubMed ID: 26707273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.